Log-Rank p=0.08, N=100 1 vs 2, HR=5.561 (0.742-41.659) 1 vs 3, 
Figure S1. Related to Figure 1
A) Validation of TAMR tumor growth. Left is the growth curves of 4 individual founder tumors (formed by injection of the TAMR cells), and right four panels show the growth patterns of the resulting TAMR tumor models with tamoxifen/no tamoxifen (n = 4-5 for each group) treatment. B) Schematic representing comparison of DNase Seq aligned with published ER and FOXA1 ChIP Seq (Hurtado, Holmes et al. 2011 ); A venn diagram was first created for ER and FOXA1 known binding sites which define subsets for 9580 coincident sites, 12,120 sites private to ER, and 61,335 sites private to FOXA1. The aggregate DNase signal profile was then plotted for each subset with a 500bp window to each side of the features. A) Assessment of mRNA expression of GRHL2 as predictor of outcome (Recurrence Free Survival (RFS) and Distant Metastasis Free Survival (DMFS)) using the Gene Analytics Tool in overall patient populations, or by PAM50 subgroup. B) Kaplan Meier-estimator of time to recurrence (RFS, months) of breast tumors derived from all patients (patient characteristics see Table S2 ), stratified based on GRHL2 protein expression (1 = low, 3 = high). Statistical significance to determine differences between groups based on scoring was determined using Log-Rank test, p = 0.08; Hazard ratios were determined using univariate Cox proportional hazards model, p=0.14.
Figure S3, related to Figure 5
A)Western blot showing efficacy of GRHL2 knockdown using three different siRNA targeting GRHL2. TamR cells were transfected with siRNA, final concentration 60nM, for 72hrs in phenol red-free DMEM:F12 containing 8% 2x charcoal-stripped FBS. After which, cells were scraped off plate and lysed with RIPA buffer. Cell lysates were resolved on SDS-PAGE and GRHL2 expression normalized to βactin and then to the control siRNA sample. Knockdown of GRHL2 protein was achieved whether the top band or all bands was assessed. This experiment was repeated with biological replicates n=3 and this figure is a representative image of such replicates. Comparison of differential gene expression in TAMR and MCF7-WS8 xenografts data with subcategories of regulatory elements indicates subset of genes increased in vivo in tamoxifen resistance, downstream of FOXA1/GRHL2 collaboration. Relative enrichment of genes differentially expressed in TAMR relative to MCF7-WS8 within 10kb of B) FOXA1 binding events alone (as in Figure 1 ), C) FOXA1 increased binding events subdivided based on histone marks (as in Figure 2B ) 
Figure S6, related to Figure 7
A) Knockdown efficiency of siRNAs against LYPD3 was assessed in TAMR cells transfected with control siRNA or 3 different siRNA against LYPD3. Cell lysates were resolved on SDS-PAGE and the LYPD3 protein levels were determined by immunoblots using antibody against LYPD3. β-actin antibody was used as normalization control. This experiment was repeated for a total of 3 times and shown is representative data. B) HCC1428-TAMR cells were transfected with RNAiMAX only (mock), siCtrl or 2 unique siRNA sequences targeting LYPD3 and monitored for cell growth for 9 days. The experiment was repeated 4 times with similar results and representative data was shown. C) TAMR tumors were established in tamoxifen-treated mice and then received further treatment with anti-LYPD3, anti-AGR2 or IgG control antibodies (15mg/kg, 2X weekly) or both anti-LYPD3 + anti-AGR2 (7.5mg/kg/antibody, 2X weekly) and were monitored over time. Average tumor volume -/+ SEM is plotted (n = 8-9 per group) and significance was determined by two-way ANOVA followed by Bonferroni's multiple comparison test. p < 0.05 as indicated by *. D) The expression of AGR2 in xenograft tumor models (MCF7-WS8, TamR and LTED) was assessed using immunoblot with anti-AGR2 antibody. Antibody against Lamin A was used as a normalization control. E) Ovariectomized J/nu mice bearing LTED (resistant to long term estrogen withdrawal) xenograft tumors were randomized to treatment with 45 mg/kg IgG or LYPD3 antibody. Data presented indicate the average tumor volume for each group (mean +/-SEM) at each time point of tumor measurement (left). Time to progression analysis (Kaplan-Meier) analysis was conducted using 2X tumor volume (twice the tumor volume at time of randomization) as an endpoint(right). High variability confounded the results of 2-way ANOVA analysis, and therefore no significant differences were detected between treatment groups. Time to progression analysis revealed a significant (p = 0.0105) delay in tumor progression. 
